Barclays PLC Boosts Stake in Astria Therapeutics, Inc. (NASDAQ:ATXS)

Barclays PLC grew its stake in shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) by 70.5% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 92,651 shares of the biotechnology company’s stock after buying an additional 38,321 shares during the quarter. Barclays PLC owned 0.16% of Astria Therapeutics worth $1,020,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in the stock. FMR LLC raised its position in shares of Astria Therapeutics by 29.2% during the 3rd quarter. FMR LLC now owns 7,822,275 shares of the biotechnology company’s stock valued at $86,123,000 after buying an additional 1,767,714 shares in the last quarter. RA Capital Management L.P. raised its position in shares of Astria Therapeutics by 1.2% during the 3rd quarter. RA Capital Management L.P. now owns 5,105,213 shares of the biotechnology company’s stock valued at $56,208,000 after buying an additional 61,457 shares in the last quarter. Vestal Point Capital LP raised its position in shares of Astria Therapeutics by 23.1% during the 3rd quarter. Vestal Point Capital LP now owns 4,000,000 shares of the biotechnology company’s stock valued at $44,040,000 after buying an additional 750,000 shares in the last quarter. Millennium Management LLC raised its position in shares of Astria Therapeutics by 13.5% during the 2nd quarter. Millennium Management LLC now owns 1,842,063 shares of the biotechnology company’s stock valued at $16,763,000 after buying an additional 218,518 shares in the last quarter. Finally, Affinity Asset Advisors LLC raised its position in shares of Astria Therapeutics by 15.4% during the 2nd quarter. Affinity Asset Advisors LLC now owns 975,606 shares of the biotechnology company’s stock valued at $8,878,000 after buying an additional 130,000 shares in the last quarter. Hedge funds and other institutional investors own 98.98% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on ATXS shares. HC Wainwright reiterated a “buy” rating and issued a $16.00 target price on shares of Astria Therapeutics in a research report on Tuesday, December 10th. Oppenheimer lifted their target price on shares of Astria Therapeutics from $26.00 to $28.00 and gave the stock an “outperform” rating in a research report on Thursday, November 14th. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Astria Therapeutics currently has an average rating of “Buy” and an average price target of $25.60.

Astria Therapeutics Stock Down 3.0 %

Shares of NASDAQ:ATXS opened at $8.88 on Tuesday. The stock has a market cap of $501.13 million, a PE ratio of -4.25 and a beta of 0.67. Astria Therapeutics, Inc. has a 52 week low of $6.58 and a 52 week high of $16.90. The company’s fifty day moving average is $10.45 and its 200 day moving average is $10.73.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.